首页> 外文期刊>Carcinogenesis >A novel regulatory loop miR-101/ANXA2/EGR1 mediates malignant characteristics of liver cancer stem cells
【24h】

A novel regulatory loop miR-101/ANXA2/EGR1 mediates malignant characteristics of liver cancer stem cells

机译:一种新型调节循环miR-101 / ANXA2 / EGR1介导肝癌干细胞的恶性特征

获取原文
获取原文并翻译 | 示例
           

摘要

Increasing evidence suggests that liver cancer stem cells (LCSCs) are the cellular determinants that promote tumor recurrence and metastases. Aberrantly expressed miRNAs were identified in LCSCs and found to play a significant role in modulating biological characteristics of LCSCs. In this study, we implemented miRNA microarrays in CD133(+) LCSCs and found miR-101 expression was downregulated. Increasing miR-101 expression repressed the metastasis and tumorigenic potential in LCSCs. Further investigations showed that ANXA2 was a novel target of miR-101. And we revealed that ANXA2 plays a critical role in acceleration of cell cycle and enhancing the migration and invasion abilities of LCSCs. Elevated ANXA2 increased activation of extracellular signal-regulated kinase (ERK) which regulated SOX2 and cell cycle-related kinases. Moreover, ERK phosphorylation inhibited the expression of early growth response 1 (EGR1) which in turn restrained the transcription of miR-101. In vivo experiments, overexpression of miR-101 produced potent inhibitory effects on the growth of LCSCs xenograft tumors as well as ANXA2 knockdown. Taken together, our findings suggest a novel regulatory loop miR-101/ANXA2/EGR1 in LCSCs and may serve as potential therapeutic targets in liver cancer.
机译:越来越多的证据表明,肝癌干细胞(LCSCs)是促进肿瘤复发和转移的细胞决定因素。在LCSCs中发现了异常表达的miRNA,并发现它们在调节LCSCs的生物学特性方面发挥了重要作用。在这项研究中,我们在CD133(+)LCSC中实施了miRNA微阵列,发现miR-101表达下调。miR-101表达的增加抑制了LCSCs的转移和致瘤潜能。进一步的研究表明,ANXA2是miR-101的一个新靶点。我们发现ANXA2在加速细胞周期、增强LCSCs的迁移和侵袭能力方面起着关键作用。ANXA2升高增加了细胞外信号调节激酶(ERK)的激活,ERK调节SOX2和细胞周期相关激酶。此外,ERK磷酸化抑制了早期生长反应1(EGR1)的表达,进而抑制了miR-101的转录。在体内实验中,miR-101的过度表达对LCSCs异种移植肿瘤的生长以及ANXA2的敲除产生了强有力的抑制作用。综上所述,我们的研究结果表明,LCSCs中存在一个新的调节环miR-101/ANXA2/EGR1,可能成为肝癌的潜在治疗靶点。

著录项

  • 来源
    《Carcinogenesis》 |2021年第1期|共12页
  • 作者单位

    Nanjing Med Univ Affiliated Suzhou Hosp Dept Lab Suzhou 215008 Jiangsu Peoples R China;

    Soochow Univ Affiliated Infect Dis Hosp Dept Pharm Suzhou 215131 Jiangsu Peoples R China;

    Soochow Univ Affiliated Infect Dis Hosp Dept Pharm Suzhou 215131 Jiangsu Peoples R China;

    Soochow Univ Affiliated Infect Dis Hosp Dept Pharm Suzhou 215131 Jiangsu Peoples R China;

    Soochow Univ Affiliated Infect Dis Hosp Dept Pharm Suzhou 215131 Jiangsu Peoples R China;

    Nanjing Med Univ Affiliated Suzhou Hosp Dept Lab Suzhou 215008 Jiangsu Peoples R China;

    Soochow Univ Affiliated Infect Dis Hosp Dept Pharm Suzhou 215131 Jiangsu Peoples R China;

    Soochow Univ Affiliated Infect Dis Hosp Dept Pharm Suzhou 215131 Jiangsu Peoples R China;

    Soochow Univ Affiliated Infect Dis Hosp Dept Pharm Suzhou 215131 Jiangsu Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号